Evidence map›Paper›PMID 34991443›Full record

ArticleBMC molecular and cell biology2022

Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.

Shijulal Nelson-Sathi, P K Umasankar, E Sreekumar, R Radhakrishnan Nair, Iype Joseph, Sai Ravi Chandra Nori, Jamiema Sara Philip, Roshny Prasad, K V Navyasree, Shikha Ramesh and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC molecular and cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Journal of tropical medicine · 2023
    Article
  9. Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies.International journal of molecular sciences · 2022
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Shijulal Nelson-SathiCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India. shijulalns@rgcb.res.in.
P K UmasankarCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India. umasankarpk@rgcb.res.in.
E SreekumarCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
R Radhakrishnan NairCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
Iype JosephCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
Sai Ravi Chandra NoriCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
Jamiema Sara PhilipCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
Roshny PrasadCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
K V NavyasreeCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
Shikha RameshCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
Heera PillaiCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
Sanu GhoshCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
T R Santosh KumarCorona Research & Intervention Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, 695014, India.
M Radhakrishna PillaiSAGENOME Private Limited, BioNest, Kochi, 683503, India.
Rajiv Gandhi Centre for Biotechnology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV-2, the causative agent of COVID-19 pandemic is a RNA virus prone to mutations. Formation of a stable binding interface between the Receptor Binding Domain (RBD) of SARS-CoV-2 Spike (S) protein and Angiotensin-Converting Enzyme 2 (ACE2) of host is pivotal for viral entry. RBD has been shown to mutate frequently during pandemic. Although, a few mutations in RBD exhibit enhanced transmission rates leading to rise of new variants of concern, most RBD mutations show sustained ACE2 binding and virus infectivity. Yet, how all these mutations make the binding interface constantly favourable for virus remain enigmatic. This study aims to delineate molecular rearrangements in the binding interface of SARS-CoV-2 RBD mutants.

resultsHere, we have generated a mutational and structural landscape of SARS-CoV-2 RBD in first six months of the pandemic. We analyzed 31,403 SARS-CoV-2 genomes randomly across the globe, and identified 444 non-synonymous mutations in RBD that cause 49 distinct amino acid substitutions in contact and non-contact amino acid residues. Molecular phylogenetic analysis suggested independent emergence of RBD mutants. Structural mapping of these mutations on the SARS-CoV-2 Wuhan reference strain RBD and structural comparison with RBDs from bat-CoV, SARS-CoV, and pangolin-CoV, all bound to human or mouse ACE2, revealed several changes in the interfacial interactions in all three binding clusters. Interestingly, interactions mediated via N487 residue in cluster-I and Y449, G496, T500, G502 residues in cluster-III remained largely unchanged in all RBD mutants. Further analysis showed that these interactions are evolutionarily conserved in sarbecoviruses which use ACE2 for entry. Importantly, despite extensive changes in the interface, RBD-ACE2 stability and binding affinities were maintained in all the analyzed mutants. Taken together, these findings reveal how SARS-CoV-2 uses its RBD residues to constantly remodel the binding interface.

conclusionOur study broadly signifies understanding virus-host binding interfaces and their alterations during pandemic. Our findings propose a possible interface remodelling mechanism used by SARS-CoV-2 to escape deleterious mutations. Future investigations will focus on functional validation of in-silico findings and on investigating interface remodelling mechanisms across sarbecoviruses. Thus, in long run, this study may provide novel clues to therapeutically target RBD-ACE2 interface for pan-sarbecovirus infections.

Indexed as

COVID-19SARS-CoV-2AnimalsHost Microbial InteractionsHumansMiceMutationPandemicsPhylogenySpike Glycoprotein, CoronavirusSpike Glycoprotein, CoronavirusACE2Binding interfaceMutationsReceptor binding domainSARS-CoV-2Spike protein

Identifiers

PMID34991443
PMCPMC8736301
OpenAlexW4225919358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.